PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA
- PMID: 31013158
- DOI: 10.4158/EP-2018-0607
PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA
Abstract
Objective: The aim of this study was to investigate the prognostic value of metabolic characteristics of metastatic lymph node (LN) using pretreatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for patients with papillary thyroid carcinoma (PTC) and metastatic lateral LN (N1b). Methods: Ninety-six PTC patients (female:male = 72:24; median age, 44.5 years) with pathologic N1b who underwent pretreatment FDG PET/CT, total thyroidectomy, and radioactive iodine ablation were retrospectively reviewed. To predict responses to initial therapy and recurrence, clinicopathologic factors and metabolic parameters were reviewed, such as sex, age, tumor size, extranodal extension, number and ratio of metastatic LNs, serum thyroglobulin, and maximum standardized uptake value (SUVmax). Results: Among the 96 PTC patients, 81 (84.4%) were classified into the acceptable response (58 excellent; 23 indeterminate) and 15 (15.6%) into the incomplete response (8 biochemical incomplete; 7 structural incomplete) by the 2015 American Thyroid Association management guideline for differentiated thyroid carcinoma. The multivariate analysis showed that SUVmax of N1b (P = .018), pre-ablation stimulated thyroglobulin level (P = .006), and the ratio of metastatic LNs (P = .018) were related to incomplete response. The cutoff value of each variable was determined by receiver operating characteristic analysis. Nine (9.4%) patients experienced recurrences (median follow-up: 50 months). The Kaplan-Meier analysis revealed that SUVmax of N1b (cutoff value: 2.3; P = .025) and ratio of metastatic LNs (cutoff value: 0.218; P = .037) were significant prognostic factors for recurrence. Conclusion: High SUVmax of N1b cervical LN on pretreatment FDG PET/CT could predict incomplete responses to initial therapy and recurrence in patients with N1b PTC. Abbreviations: ATA = American Thyroid Association; DTC = well-differentiated thyroid carcinoma; FDG = F-18 fluorodeoxyglucose; IQR = interquartile range; LN = lymph node; N1b = metastatic lateral cervical lymph node; PET/CT = positron emission tomography/computed tomography; PTC = papillary thyroid carcinoma; RAI = radioactive iodine; ROC = receiver operating characteristic; SUVmax = maximum standardized uptake value; Tg = thyroglobulin; USG = ultrasonography.
Similar articles
-
SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.Endocr Pract. 2019 Sep;25(9):887-898. doi: 10.4158/EP-2018-0583. Epub 2019 Jun 6. Endocr Pract. 2019. PMID: 31170371
-
Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.Head Neck. 2018 Jan;40(1):94-102. doi: 10.1002/hed.24967. Epub 2017 Nov 11. Head Neck. 2018. PMID: 29130586
-
UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.Endocr Pract. 2019 Dec;25(12):1286-1294. doi: 10.4158/EP-2019-0155. Epub 2019 Aug 14. Endocr Pract. 2019. PMID: 31412228
-
Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.Semin Nucl Med. 2006 Jul;36(3):194-205. doi: 10.1053/j.semnuclmed.2006.03.002. Semin Nucl Med. 2006. PMID: 16762610 Review.
-
Pancreatic metastasis from papillary thyroid carcinoma: Case report and literature review.Hell J Nucl Med. 2021 May-Aug;24(2):140-148. doi: 10.1967/s002449912354. Epub 2021 Aug 6. Hell J Nucl Med. 2021. PMID: 34352049 Review.
Cited by
-
Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma.Cancers (Basel). 2022 Jul 28;14(15):3677. doi: 10.3390/cancers14153677. Cancers (Basel). 2022. PMID: 35954338 Free PMC article.
-
Nuclear Medicine Imaging in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-I.Nucl Med Mol Imaging. 2025 Feb;59(1):1-7. doi: 10.1007/s13139-024-00885-y. Epub 2024 Oct 19. Nucl Med Mol Imaging. 2025. PMID: 39881973 Review.
-
Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review.Front Oncol. 2021 May 13;11:648658. doi: 10.3389/fonc.2021.648658. eCollection 2021. Front Oncol. 2021. PMID: 34055616 Free PMC article.
-
Impact of positive lymph nodes and RAI therapy on survival in N1b papillary thyroid carcinoma.Front Endocrinol (Lausanne). 2025 May 22;16:1551075. doi: 10.3389/fendo.2025.1551075. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40475988 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous